RT Journal Article SR Electronic T1 Clinical course and outcomes of critically ill COVID-19 patients in two successive pandemic waves JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.02.26.21251848 DO 10.1101/2021.02.26.21251848 A1 Athanasios Chalkias A1 Ioannis Pantazopoulos A1 Nikolaos Papagiannakis A1 Anargyros Skoulakis A1 Eleni Laou A1 Konstantina Kolonia A1 Nicoletta Ntalarizou A1 Dimitrios Ragias A1 Christos Kampolis A1 Luis GarcĂ­a de Guadiana Romualdo A1 Konstantinos Tourlakopoulos A1 Athanasios Pagonis A1 Salim S Hayek A1 Jesper Eugen-Olsen A1 Konstantinos Gourgoulianis A1 Eleni Arnaoutoglou YR 2021 UL http://medrxiv.org/content/early/2021/04/15/2021.02.26.21251848.abstract AB Rationale The progress of COVID-19 from moderate to severe may be precipitous, while the heterogenous characteristics of the disease pose challenges to the management of these patients.Objectives To characterize the clinical course and outcomes of critically ill patients with COVID-19 during two successive waves.Methods We leveraged the multi-center SuPAR in Adult Patients With COVID-19 (SPARCOL) study and collected data from consecutive patients requiring admission to the intensive care unit from April 1st to December 31st, 2020.Measurements and Main Results Of 252 patients, 81 (32%) required intubation and mechanical ventilation. Of them, 17 (20.9%) were intubated during the first wave, while 64 (79%) during the second wave. The most prominent difference between the two waves was the overall survival (first wave 58.9% vs. second wave 15.6%, adjusted p-value=0.006). This difference is reflected in the prolonged hospitalization during the first wave. The mean ICU length of stay (19.1 vs. 11.7 days, p=0.022), hospital length of stay (28.5 vs. 17.1 days, p=0.012), and days on ventilator (16.7 vs. 11.5, p=0.13) were higher during the first wave. A significant difference between the two waves was the development of bradycardia. In the first wave, 2 (11.7%) patients developed sinus bradycardia only after admission to the intensive care unit, while in the second wave, 63 (98.4%) patients developed sinus bradycardia during hospitalization.Conclusions Survival of critically ill patients with COVID-19 was significantly lower during the second wave. The majority of these patients developed sinus bradycardia during hospitalization.Competing Interest StatementJesper Eugen-Olsen is a co-founder, shareholder and CSO of ViroGates A/S and is mentioned inventor on patients on suPAR owned by Copenhagen University Hospital Hvidovre, Denmark. All other authors report no conflicts of interest.Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was provided by the Ethical Committee of the University Hospital of Larisa (IRB no. 17543), Larisa, Greece on 24 April 2020. The study was performed according to national and international guidelines. Written informed consent was obtained from the patients.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData can be made available upon request through a collaborative process